(Reuters) -Avacta Group, a British biotech company, announced Monday that it would stop selling its COVID-19 antigen lateral flux test, AffiDX. This was to replace the antibodies and increase its detection rate of the Omicron coronavirus variant with lower viral loads.

Although the test is able to detect Omicron in very high levels, it is not possible for the London-listed firm to do so. However, Avacta’s tests showed that AffiDX was less sensitive than other Omicron variants at lower viral loads.

As Omicron threatens to dominate the global marketplace, scientists and governments are working together to boost defenses.

Roche’s newly purchased unit TIB Molbiol developed in December three test kits that can help scientists detect Omicron mutations.

Avacta, along with some test-makers, had to remove some COVID-19 testing products from British markets after a new system of review was established. It has yet not approved their previous accepted products.